Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.52 |
| ▸ | SKP1 | P63208 | 2/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 3/20 | 0.46 |
| ▸ | ACACA | Q13085 | 3/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15728295 | 0.93 | TRPA1 (0.54) | CKS1BSKP1SKP2NAMPTKDM4E | |
| SCHEMBL8222029 | 0.88 | CKS1B (0.53) | CKS1BSKP1SKP2DRD2DRD4 | |
| SCHEMBL12916519 | 0.87 | GPR119 (0.57) | CKS1BSKP1SKP2DRD2NAMPT | |
| SCHEMBL3711639 | 0.87 | CKS1B (0.51) | CKS1BSKP1SKP2DRD2NOTUM | |
| SCHEMBL10232155 | 0.87 | TRPA1 (0.55) | CKS1BSKP1SKP2DRD2DRD4 | |
| SCHEMBL16394312 | 0.86 | CKS1B (0.53) | CKS1BSKP1SKP2DRD2DRD4 | |
| SCHEMBL803332 | 0.86 | CKS1B (0.56) | CKS1BSKP1SKP2DRD2NAMPT | |
| SCHEMBL5653703 | 0.86 | CKS1B (0.53) | CKS1BSKP1SKP2DRD2NAMPT | |
| SCHEMBL4116060 | 0.85 | CKS1B (0.64) | CKS1BSKP1SKP2DRD2NAMPT | |
| SCHEMBL29311592 | 0.85 | CKS1B (0.53) | CKS1BSKP1SKP2DRD2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| EP-2234973-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | CKS1B 4680/4885SKP1 3381/4885SKP2 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.